The total return over the past 12 months is -76.90% vs. +16.94% for the S&P 500. So far it's up -82.76% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (76.90%) | (28.05%) | (21.68%) | (20.02%) | (15.19%) | (15.34%) |
| Total Return CAGR | (76.90%) | (28.05%) | (21.68%) | (20.02%) | (15.19%) | (15.34%) |
| Revenue CAGR | (94.63%) | (57.88%) | (41.05%) | +5.58% | (3.77%) | +7.41% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
EyePoint Pharmaceuticals, Inc. (EYPT)
| Year | Start price | End price | EYPT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $18.27 | $3.15 | (82.76%) | +14.51% | (97.27%) |
| 2025 | $7.45 | $18.27 | +145.23% | +17.72% | +127.51% |
| 2024 | $23.11 | $7.45 | (67.76%) | +24.89% | (92.65%) |
| 2023 | $3.50 | $23.11 | +560.29% | +26.19% | +534.10% |
| 2022 | $12.24 | $3.50 | (71.41%) | (18.17%) | (53.24%) |
| 2021 | $6.58 | $12.24 | +86.02% | +28.74% | +57.28% |
| 2020 | $15.50 | $6.58 | (57.55%) | +18.37% | (75.92%) |
| 2019 | $18.90 | $15.50 | (17.99%) | +31.22% | (49.21%) |
| 2018 | $10.80 | $18.90 | +75.00% | (4.56%) | +79.56% |
| 2017 | $17.10 | $10.80 | (36.84%) | +21.70% | (58.54%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
